AAAAAA
Results:
1-7
|
Results: 7
Authors:
Sullivan, JT
Lettieri, JT
Liu, P
Heller, AH
Citation: Jt. Sullivan et al., The influence of age and gender on the pharmacokinetics of moxifloxacin, CLIN PHARMA, 40, 2001, pp. 11-18
Authors:
Isaacsohn, J
Zinny, M
Mazzu, A
Lettieri, J
Heller, AH
Citation: J. Isaacsohn et al., Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults, EUR J CL PH, 56(12), 2001, pp. 897-903
Authors:
Barrett, JS
Batra, V
Chow, A
Cook, J
Gould, AL
Heller, AH
Lo, MW
Patterson, SD
Smith, BP
Stritar, JA
Vega, JM
Zariffa, N
Citation: Js. Barrett et al., PhRMA perspective on population and individual bioequivalence, J CLIN PHAR, 40(6), 2000, pp. 561-570
Authors:
Barrett, JS
Batra, V
Chow, A
Cook, J
Gould, AL
Heller, AH
Lo, MW
Patterson, SD
Smith, BP
Stritar, JA
Vega, JM
Zariffa, N
Citation: Js. Barrett et al., Update to the PhRMA Perspective on Population and Individual Bioequivalence, J CLIN PHAR, 40(6), 2000, pp. 571-572
Authors:
Shah, A
Liu, MC
Vaughan, D
Heller, AH
Citation: A. Shah et al., Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg 10 mL or 500 mg 5 mLsuspension and the effect of food on the absorption of ciprofloxacin oral suspension, J ANTIMICRO, 43, 1999, pp. 49-54
Authors:
Sullivan, JT
Woodruff, M
Lettieri, J
Agarwal, V
Krol, GJ
Leese, PT
Watson, S
Heller, AH
Citation: Jt. Sullivan et al., Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone, ANTIM AG CH, 43(11), 1999, pp. 2793-2797
Authors:
Stein, E
Isaacsohn, J
Stoltz, R
Mazzu, A
Liu, MC
Lane, C
Heller, AH
Citation: E. Stein et al., Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mgdose of cerivastatin in patients with primary hypercholesterolemia, AM J CARD, 83(10), 1999, pp. 1433-1436
Risultati:
1-7
|